Introduction
Although IL-2 plays an important role in the development and expansion of effector T cells, recent studies have demonstrated that IL-2 is also critical for the establishment and maintenance of immune tolerance 1, 2 . Since autoimmunity is the primary immunologic abnormality in IL-2 deficient mice, it has been proposed that the negative regulatory effects of IL-2 are the predominant functional effects of this cytokine in vivo 3, 4 . The principal mechanism whereby IL-2 promotes immune tolerance appears to be through its role in the generation and maintenance of CD4+CD25+ regulatory T cells (Treg). In particular, experiments in animal models have demonstrated that IL-2 controls Treg homeostasis in blood and peripheral lymphoid tissues [5] [6] [7] [8] . Recent clinical studies in patients with HIV and cancer have shown that treatment with recombinant IL-2 can induce the expansion of Treg in peripheral blood [9] [10] [11] [12] . Some of these studies were performed in young adult patients with sarcoma who were lymphopenic due to previous chemotherapy 11 . Treg expansion following IL-2 administration was more pronounced in lymphopenic patients, suggesting that homeostatic peripheral expansion also contributed to the proliferation of Treg cells in vivo.
Even though IL-2 is essential for Treg development, the cellular pathways whereby IL-2 influences the proliferation and function of these cells have not been well defined. Treg constitutively express CD25, the α subunit of the trimeric receptor for IL-2. Treg therefore express the complete high affinity IL-2Rαβγ complex and can presumably respond to physiologically low concentrations of IL-2 in vivo. IL-2R signaling is primarily mediated through activation of JAK1 and JAK3 with subsequent phosphorylation and activation of STAT3 and STAT5 13 . These activated transcription factors translocate to the nucleus where they initiate a complex series of transcriptional events leading to many of the functional effects of IL-2 stimulation. IL-2R triggering also leads to activation of other signaling pathways including mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) and these pathways also contribute to the varied functional effects of IL-2 on immune cells. Within Treg however, previous studies have shown that IL-2 primarily induces JAK/STAT signaling rather than PI3K
signaling and this may explain some of the different functional effects of IL-2 on Treg and effector T cells 14, 15 .
Recent studies defining the mechanisms whereby Treg cells mediate immune suppressive
functions have demonstrated that FOXP3 plays a critical role in the regulatory functions of CD4+CD25+ T cells in humans as well as in animal models [16] [17] [18] . These studies include the demonstration that specific mutations of FOXP3 result in severe functional deficiencies of Treg in mice and humans [19] [20] [21] . Moreover, forced expression of FOXP3 appears to result in acquisition of immune suppressive functions 16, 18 . FOXP3 gene expression also appears to be highly restricted to CD4+CD25+ Treg and has therefore become a very useful marker for the specific detection and enumeration of Treg as well as a surrogate marker for assessment of functional immune suppressive activity.
In the present studies, we show that IL-2 signaling directly targets the FOXP3 gene in CD4+CD25+ 
Patients and Methods

Patients and samples
All patients included in this study were enrolled in clinical protocols approved by the Dana-Farber Cancer Institute Investigational review board (IRB). Written informed consent was obtained from each patient prior to sample collection. The clinical toxicities associated with prolonged administration of low-dose IL-2 and effects of IL-2 infusions on peripheral blood NK cells have been described previously 22, 23 . Patient peripheral blood mononuclear cells (PBMC) were isolated from blood samples by density gradient centrifugation and cryopreserved in aliquots before being analyzed. Patient characteristics including disease, age, IL-2 treatment dose and duration are summarized in Table 1 .
In vitro cell culture and reagents
PBMC and purified primary cells were cultured in RPMI 1640 supplemented with 10%
heat inactivated human AB serum, 4 mM glutamine, 1 mM sodium pyruvate, 10 mM
Hepes and antibiotics. NKL cell line was cultured in the same medium supplemented with 10% heat inactivated fetal calf serum instead of human serum. Recombinant human IL-2 (AMGEN, Thousand Oaks, CA) was added to cultures at a concentration of 100 Units/ml unless otherwise stated.
Flow cytometry
PBMC were thawed and labeled with anti-CD4-PE (T4) and anti-CD25-FITC (IL-2R1) or anti-CD56-PE (NKH1; Beckman Coulter, Fullerton, CA). Labeled cells were analyzed using a Cytomics FC500 flow cytometer (Beckman Coulter). The frequency of each cell subset was calculated based on the percentage of positive cells in the total lymphocyte gate. For CD4+CD25+ cells, values were subsequently readjusted to represent percent of these cells within the CD3+ lymphocyte population. For intra-cellular staining, cells were first labeled with anti-CD4-PC5 (Coulter), fixed and permeabilized using a fix/perm kit (eBioscience, San Diego, CA) according to the manufacturer's instructions then labeled with anti-FOXP3-PE mab (PCH101, eBioscience).
Cell sorting
PBMC from healthy donors were labeled with anti-CD4 FITC (T4) and anti-CD25-PE (IL-2R1). CD4+CD25 bright and CD4+CD25-cells were then isolated using a BD FACSAria cell sorting instrument. For NK cells and CD4+ T cell populations, PBMC collected from healthy individuals or from patients during IL-2 treatment were labeled with anti-CD4-FITC (T4), anti-CD56-PE N901 (NKH-1) and anti-CD3-PC5 (UCHT1) from Beckman Coulter. NK cells were isolated based on a CD3-CD56+ phenotype.
CD3+CD4+ cell populations were also isolated and used as reference populations in FOXP3 expression experiments. Sorted cell populations were confirmed to be over 95% pure.
Quantitative PCR
Total RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA).
Complementary DNA was then prepared from an average of 500ng total RNA using the superscripIII cDNA first strand synthesis kit (Invitrogen 
Luciferase reporter gene assays
Treatment with 5-aza-2'-deoxycytidine
NKL cells or primary CD3-CD56+ NK cells isolated from healthy blood were cultured for 2 days in complete medium supplemented with 100 U/ml IL-2 and 5-aza-2'-deoxycytidine (Sigma) at a final concentration of 1 µM or 10µM as indicated. Cells were then thoroughly washed and incubated in the same medium with 5-aza-2'-deoxycytidine but without IL-2 for an additional 24h. IL-2 (100 U/ml) was added to half the cultures and cells were incubated for 18h before being tested for the expression of FOXP3.
Results
IL-2 up-regulates the expression of FOXP3 in CD4+CD25+ but not CD4+CD25-T cells.
We investigated the effect of IL-2 on the expression of FOXP3 in CD4+CD25+ bright Treg and CD4+CD25-T cells purified from healthy individuals. As illustrated in Figure 1A , To confirm that this particular sequence had STAT dependent transcriptional activity, we tested the ability of this region to regulate expression of a luciferase reporter gene. This highly conserved region encompassing the 2 STAT responsive elements was amplified by PCR from genomic DNA and inserted into a plasmid vector upstream from a luciferase reporter gene. We also generated a mutated construct by disrupting the 2 putative STAT binding motifs using site-directed mutagenesis (shown in red in Figure   2A ). When transfected into 293 cells, both wild-type and mutated constructs showed little reporter activity ( Figure 2B ). In contrast, when the wild-type construct was co-transfected with a constitutively activated form of STAT5, STAT5a1*6 25 , a prominent induction of luciferase activity was observed. The signal was abrogated when the mutated version of the FOXP3 intronic region was used, indicating that the 2 STAT binding elements were required for this activity. Similarly, co-transfection of the wild-type FOXP3 intronic element with a constitutively activated form of STAT3, STAT3C 26 , resulted in substantial reporter gene activity. Again, the activity was abrogated when a reporter construct with mutated STAT motifs was used.
Administration of low dose recombinant IL-2 induces the expansion of CD4+CD25+ FOXP3+ T cells in vivo
Based on these in vitro findings, we next examined the influence of IL-2 on Treg in vivo.
Twenty-one patients had previously received prolonged courses of low-dose recombinant IL-2 (2 X 10 5 to 1.5 X 10 6 Units/m 2 /day for 3 months) for advanced solid tumors (N=12)
or following T-cell depleted allogeneic hematopoietic stem cell transplantation (HSCT)
for chronic myelocytic leukemia (N=9). The effects of IL-2 infusions on CD3+CD56-T cells and CD3-CD56+ NK cells in these patients have been reported previously 22, 23, 27 . In the present study, blood samples collected prior to IL-2 therapy and during treatment were assessed for both phenotypic and molecular markers of Treg. Patient characteristics, IL-2 doses, and length of treatment at the time of testing are summarized in Table 1 are shown in Figure 3C . 
Effects of IL-2 on CD4+CD25+ cells and FOXP3 expression in vivo are transient
Low dose IL-2 therapy induces the expansion of CD3-CD56+ NK cells but does not induce FOXP3 expression in NK cells.
Previous studies have demonstrated the expansion of CD3-CD56+ NK cells in vivo following IL-2 therapy. We confirmed this effect in our patient cohort ( Figure 5A ). All 
FOXP3 expression in NK cells is repressed by DNA methylation
To explain the lack of FOXP3 expression in NK cells following IL-2 therapy, we hypothesized that this gene might be regulated at a different level, possibly by DNA methylation. To test this hypothesis, we subjected the human NK cell line NKL to 2 different doses of the demethylating agent 5-aza-2'-deoxycytidine for 3 days before stimulating the cells with IL-2. As shown in Figure 6A , IL-2 induced the expression of . Other investigations have shown that IL-2 is also involved in the suppressive function of these cells 28, 29 . However, despite this growing body of data, the mechanism whereby IL-2 controls Treg homeostasis remains unknown. It is still particularly unclear as to how IL-2 selectively regulates Treg in vivo among other immune cells that also appear to respond to this cytokine in vitro. In our studies we describe a direct pathway linking IL-2 signaling to the expression of the Further prospective analysis of patients receiving low dose IL-2 will be needed to better define the relationships between the duration of IL-2 therapy, the extent of Treg proliferation in vivo and the functional capacity of these cells.
As reported in earlier studies, prolonged administration of low dose IL-2 results in the vigorous expansion of CD3-CD56+ NK cells in vivo 35, 36 . Although NK cells clearly respond to IL-2 in vivo, these cells did not express FOXP3 following IL-2 therapy. Since IL-2 signaling in NK cells is also known to activate STAT3 and STAT5 37,38 the lack of Since its first characterization as a T-cell growth factor, IL-2 has been used extensively to enhance T cell proliferation and T cell function in vitro and in vivo 39 . More than 15 years ago, we began a series of clinical trials investigating the effects of therapy with low-dose IL-2 on tumor immunity in vivo 27, 35, 40 . In most patients, daily IL-2 treatment was continued for a 3 month period and no concomitant chemotherapy or immunotherapy was administered. Some of these studies were undertaken in patients who had recently engrafted with allogeneic hematopoietic stem cells 22, 23 . [41] [42] [43] . In fact, some of these clinical trials have demonstrated reduced effector T cell responses in cohorts that received IL-2 42 .
As the ability to specifically identify Treg has improved, many studies have identified either quantitative or functional defects in these cells as potential contributors to autoimmune diseases 44 . In a recent clinical study we showed that poor reconstitution of CD4+CD25+FOXP3+ Treg following allogeneic HSCT correlates with the development of chronic GVHD 45 . Moreover, recovery of normal levels of Treg was associated with resolution of clinical manifestations of disease. Results of several preclinical models support the ability of Treg to suppress allo-immunity and the pathologic manifestations of GVHD [46] [47] [48] [49] . Moreover, previous studies in murine models have shown that IL-2 administered after allogeneic HSCT resulted in the abrogation of GVHD 50, 51 . In a xenogeneic model, IL-2 was not able to induce GVHD mediated by human T cells 52 .
Taken together these studies suggest that low dose IL-2 therapy may provide a mechanism for selective expansion of Treg in patients with active GVHD. A similar therapeutic approach may also be evaluated in autoimmune diseases where deficiencies in Treg number or functional capacity have been well documented. Since our studies suggest that this can be accomplished with relatively low doses of IL-2 that have not been associated with severe toxicities, this approach may be safely tested in carefully designed clinical trials. Table 1 ). Patients with solid tumors are represented with light gray histograms; patients after allogeneic HSCT are represented with black histograms. (B) FOXP3 expression was assessed in the same samples collected during IL-2 treatment and after completion of therapy (Table 1) .
Percent changes were calculated using values obtained with these 2 sets of samples. Figure 5A
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